Project Grant R01HL183196
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $853K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Boston Children's Hospital $1,561,052 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate pulmonary ionocyte function and development using human induced pluripotent stem cell-derived airway epithelium. Performance runs through June 30, 2030, in Boston, Massachusetts. The project addresses gaps in understanding how pulmonary ionocytes—rare airway cells marked by FOXI1 and ASCL3 expression and...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $712,630 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate functional heterogeneity of alveoli and early responses to airborne agents. The recipient will develop and apply the Crystal Ribcage, a novel intravital imaging platform, to visualize real-time, high-resolution dynamics of the intact, ventilating lung. The research will define the anatomy, physiology,...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $894,314 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop improved prediction and mechanistic understanding of chronic obstructive pulmonary disease exacerbations by integrating multi-trait genetics, proteomics, and deep learning methods. The research comprises three specific aims. In Aim 1, the recipient will develop a multi-trait polygenic risk score integrating...
- The National Heart, Lung, and Blood Institute awarded The University of North Texas Health Science Center at Fort Worth $426,550 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a bioengineering modular gene delivery system for lung-targeted transgene expression. The project addresses systemic gene therapy for monogenic lung diseases including cystic fibrosis, alpha-1-antitrypsin deficiency, and pulmonary arterial hypertension. The recipient...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $570,666 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a streamlined base editor reengineering platform that enhances gene editing specificity and selectivity for therapeutic applications. The recipient will establish an engineering platform to accelerate base editor development by integrating a naturally occurring...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $268,500 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct multi-omic and network analysis investigating the role of X-linked transcription factors in chronic obstructive pulmonary disease heterogeneity. The research applies gene regulatory network analysis to multi-omic datasets from blood and lung tissue across four large COPD cohort studies (COPDGene, LTRC,...
- The National Heart Lung and Blood Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $426,250 to the University Of Kansas Medical Center Research Institute, Inc. on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop inhaled BK channel potentiators as a mutation-agnostic treatment for mucus plugging in cystic fibrosis. The recipient will tether R-vanzacaftor to nanosponges as part of a cell-targeting...
- The National Heart, Lung, and Blood Institute awarded The Washington University $545,304 on July 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into extracellular vesicles as a prenatal rescue therapy for abnormal lung vasculature development in congenital diaphragmatic hernia. The project investigates stem cell-derived nanoparticles called extracellular vesicles that contain bioactive molecules critical for normal lung development. Preliminary...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Women's Hospital Inc. $1.789 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds integrative computational-experimental approaches to identify rare coding variants that influence lipid metabolism and cardiovascular disease risk. The research combines large-scale population cohort data with high-throughput functional screening using base and prime...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $825,533 for Project Grant R01HL182745 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates glycorna-based control of angiogenesis through heparan sulfate binding growth factors. Research focuses on how vascular endothelial growth factor (VEGF-A) orchestrates vascular and cardiac development by binding...